This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Example of description text sitting alongside header
Example of description text sitting alongside header
Menu
Close
Adverse event reporting can be found at the bottom of the page
Menu
Close
Prescribing information for relevant Pfizer oncology biosimilars and Adverse Event reporting information can be found at the bottom of the page.
Biological therapy provides a targeted and individualised approach that has revolutionised oncology treatment.1 The introduction of biosimilars has increased the number of therapeutic options available to healthcare professionals, providing cost-effective treatment options with a range of additional benefits and features.
In oncology, a number of biosimilars have demonstrated safety and efficacy comparable to their reference products, based on clinical trial data, real-world evidence, and the product’s physical and chemical properties. Taken together, the evidence supports the use of these biosimilars as equivalent therapeutic options to reference products when considering treatment options for people with certain cancers.2
Pfizer is committed to ensuring high standards for biosimilar quality, regulatory compliance, and supplying fast, flexible solutions across the full manufacturing and supply chain spectrum.
Pfizer has a portfolio of biosimilars on the market, including both cancer therapies and other biosimilar medicines, to give patients various treatment options.
Pfizer's biosimilars are produced to meet the same high-quality standards as Pfizer’s other biologics – using the same robust protocols for monitoring quality throughout every stage of the manufacturing process.
| Trazimera® (trastuzumab) | Nivestim® (filgrastim) |
| Ruxience®▼ (rituximab) | Retacrit® (epoetin zeta) |
| Zirabev®▼ (bevacizumab) |
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2024 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024